Surgery and radioablation therapy combined: Introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH

European Journal of Endocrinology

Volumn 161, Issue 5, 2009, Pages 763-769

  Emmanouilidis, Nikos ^a   Müller, Jörg A ^a   Jäger, Mark D ^a   Kaaden, Stephan ^a   Helfritz, Fabian A ^a   Güner, Zeynep ^a   Kespohl, Holger ^a   Knitsch, Wolfgang ^a   Knapp, Wolfram H ^a   Klempnauer, Jürgen ^a   Scheumann, Georg F W ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; MALE; MEDICAL LEAVE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCINTIGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR; URINE;

ADULT; CARCINOMA, PAPILLARY, FOLLICULAR; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 70449732263     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0641     Document Type: Article

References (19)

1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999 9 421-427. (Pubitemid 29244917)
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
3. Degroot LJ, Kaplan EL, McCormick M & Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424. (Pubitemid 20261828)
4. Sweeney DC & Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinology and Metabolism Clinics of North America 1995 24 803-839.
5. Dow KH, Ferrell BR & Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613-619. (Pubitemid 27371801)
6. Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147-1155. (Pubitemid 41720721)
7. Davids T, Witterick IJ, Eski S, Walfish PG & Freeman JL. Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope 2006 116 250-253.
8. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, Degroot LJ, Curran P, McEllin K, Reynolds J, Robbins J & Weintraub BD. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). Journal of Clinical Endocrinology and Metabolism 1994 78 188-196. (Pubitemid 24026771)
9. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, Degroot LJ, Daniels GH, Ross DS & Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888-896. (Pubitemid 27408571)
10. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E & Weston AR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology 2006 155 405-414. (Pubitemid 44463946)
11. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M & De Pouvourville G. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with thyrogen and thyroid hormone withdrawal. European Journal of Endocrinology 2007 156 531-538. (Pubitemid 46796519)
12. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, Degroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR III, Cavalieri RR, Spencer CA, Mcellin K, Weintraub BD & Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877-3885. (Pubitemid 30644169)
13. 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005 15 371-376.
14. Pitoia F, Tamer EE, Schere DB, Passerieu M, Bruno OD & Niepomniszcze H. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina 2006 66 125-130. (Pubitemid 43732838)
15. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M & Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 2006 91 926-932. (Pubitemid 43357760)
16. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubieniecka B, Hasse-Lazar K, Turska M & Zajusz A. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1077-1086. (Pubitemid 36988219)
17. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A & Pacini F. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. European Journal of Endocrinology 2001 144 5-11. (Pubitemid 32126906)
18. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC & Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 2006 91 878-884. (Pubitemid 43357753)
19. Blamey S, Barraclough B, Delbridge L, Mernagh P, Standfield L & Weston A. Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ Journal of Surgery 2005 75 10-20. (Pubitemid 40394697)